Cipla Ltd
Cipla Limited, founded in 1935 by Dr. K.A. Hamied as Chemical Industrial & Pharmaceutical Laboratories Ltd, is a leading Indian multinational pharmaceutical company headquartered in Mumbai. Ranked as the third-largest pharma company in India, it specializes in affordable, high-quality, complex generic medicines, particularly in respiratory, anti-retroviral, and cardiovascular segments. With over 1,500 products across 50+ dosage forms, Cipla operates 46 manufacturing sites in 74+ markets, driven by its ethos of “Caring for Life”.
Shareholding Pattern (Dec 2025)
Financial Summary
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 |
| Sales – | 22,753 | 25,774 | 27,548 |
| Sales Growth | 4.55% | 13.28% | 6.88% |
| Expenses + | 17,726 | 19,483 | 20,420 |
| Operating Profit | 5,027 | 6,291 | 7,128 |
| OPM % | 22% | 24% | 26% |
| Tax % | 30% | 27% | 22% |
| Net Profit + | 2,833 | 4,154 | 5,269 |
| EPS in Rs | 34.71 | 51.05 | 65.28 |
Final Outlook
The final outlook for Cipla Limited in an equity research report reflects a positive medium-to-long-term growth trajectory supported by consistent financial performance, strong operational efficiency, and a diversified global presence across key pharmaceutical markets. Based on the company’s recent annual and quarterly results, Cipla has demonstrated stable revenue growth and improving profitability, indicating a resilient business model in the competitive pharmaceutical industry.
During FY2025, the company reported consolidated revenue of approximately ₹27,548 crore, representing around 7–8% year-on-year growth compared with ₹25,774 crore in FY2024. Net profit for the year increased significantly to about ₹5,273 crore, reflecting nearly 28% growth over the previous fiscal year. This improvement in profitability was driven by strong performance across major markets including India, the United States, South Africa, and Europe, along with a better product mix and operational efficiencies. The company also maintained strong profitability margins, with EBITDA margins close to 25–26%, indicating effective cost management and improved operating leverage.
The financial performance and strategic positioning of Cipla indicate a stable and fundamentally strong company with consistent earnings growth and solid market presence. The company’s strong balance sheet, diversified geographic revenue streams, expanding product pipeline, and improving profitability provide a supportive outlook for sustained growth. Based on these factors, the overall investment outlook for Cipla remains positive, with the company expected to deliver steady revenue expansion, margin stability, and long-term shareholder value creation.
